FIELD: chemistry.
SUBSTANCE: process for the preparation of a compound of formula (III), including the reaction of a compound of formula (I) with compounds of formula (II) in the presence of an acid catalyst, where X represents –N= or CR3; R1 is hydrogen or C6-10 aryl optionally substituted with C1-6 alkyl or C1-6 alkoxy; R2 is hydrogen, C1-6 alkyl, -YR10, NR112; Y is a single bond or -S-; R10 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkyl-C6-10 aryl, C1-6 alkyl-C3-8 cycloalkyl, 5-6 membered heteroaryl containing 1-2 heteroatoms selected from nitrogen and sulfur, or C6-10 aryl optionally substituted with alkyl, C1-6 alkoxy or nitro; R11 is hydrogen or two R11 together with N combine to form morpholinyl; R4 is hydrogen or C1-6 alkyl; or R1 and R3 form an annelated benzene ring; R6 and R8 are hydrogen; R is C1-6 alkyl or C2-6 alkenyl; or two R groups together form (CH2)m; or one or two R groups together with R6 and/or R8 form one or two (CH2)n groups; n is an integer from 2 to 3; m is an integer from 4 to 5 to form a compound of formula (III).
EFFECT: new effective method for obtaining a compound of formula (III) with a high yield.
6 cl, 27 ex
Title |
Year |
Author |
Number |
2-((4-(4-(BENZYLOXY)PYRIMIDIN-2-YL)PIPERAZIN-1-YL)METHYL)-1H-BENZO[d]IMIDAZOLE DERIVATIVES AS LOW-MOLECULAR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS |
2024 |
- Tolkacheva Elena Vladimirovna
- Salakhov Tagir Lenarovich
- Saliev Aleksandr Yurevich
- Krasnodubets Alisa Mikhajlovna
- Ivanov Roman Alekseevich
- Chernyshov Vladimir Vladimirovich
|
RU2838323C1 |
COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
2022 |
- Lee, Chang Sik
- Lee, Jaewon
- Lee, Jae Young
- Park, Yesong
- Gwak, Dalyong
- Kim, Hyunjin Michael
|
RU2840068C2 |
TAXANE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT |
1994 |
- Ivao Odzima
- Ehtsio Bombardelli
|
RU2137764C1 |
DERIVATIVES OF ANTHRANILIC ACID OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS, INTERMEDIATE COMPOUNDS USED FOR THEIR SYNTHESIS AND DRUG |
1994 |
- Fumikhiro Ozaki
- Kejdzhi Isibasi
- Khironori Ikuta
- Khiroki Isikhara
- Sigeru Souda
|
RU2128644C1 |
IMIDAZOTRIAZINONE COMPOUNDS |
2011 |
- Ripka Emi
- Shapiro Gideon
- Makrajner Endrju
|
RU2603140C2 |
METHOD FOR SYNTHESIS OF NOVEL CHIRAL LIGAND, METAL CHELATE, VARIOUS UNNATURAL AMINO ACIDS, MARAVIROC AND MAIN INTERMEDIATE COMPOUNDS THEREOF |
2017 |
- Liu Hong
- Wang Jiang
- Zhou Shengbin
- Peng Panfeng
- Nian Yong
- Wang Shuni
- Shu Shuangjie
- Shen Hao
- Jiang Hualiang
- Chen Kaixian
|
RU2727723C1 |
INHIBITORS OF TWO SITES OF BINDING ACETYLCHOLINESTERASE FOR TREATMENT OF THE ALZHEIMER'S DISEASE |
2003 |
- Martines Khil Ana
- Dorronsoro Dias Isabel'
- Rubio Arr'Eta Laura
- Alonso Gordil'O Diana
- Fuehrtes Uehrta Ana
- Morales-Alselaj Susana
- Del' Monte Mil'Jan Marija
- Garsia Palomero Ehster
- Usan Ehkhea Paola
- De Austria Selija
- Medina Padil'Ja Migel'
|
RU2325379C2 |
COMPOUNDS BASED ON 7-SUBSTITUTED PYRROLOTRIAZINE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND METHODS FOR THEIR PREPARATION AND APPLICATION |
2018 |
- Yang, Chunhao
- Meng, Linghua
- Xiang, Haoyue
- Li, Jing
- Zhang, Xi
- Wang, Xiang
- Tan, Cun
- He, Qian
- Ding, Jian
- Chen, Yi
|
RU2745548C1 |
1,2,3,4-TETRAHYDROPYRAZOLO-[5,1-C]-(1,2,4)-TRIAZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION INHIBITING PRODUCING AN INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, METHOD OF PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PATIENTS WITH DISEASES MEDIATED BY INTERLEUKIN AND TUMOR NECROSIS FACTOR |
1994 |
- Esio Kavai
- Khitosi Jamazaki
- Khirokazu Tanaka
- Teruo Oku
|
RU2124517C1 |
PYRROLE AND PYRAZOLE DAAO INHIBITORS |
2004 |
- Fang K. Kevin
- Khopkins Set
- Kheffernan Mishel
- Chitil Majlan
|
RU2361862C2 |